David Scadden

Board Director

Director

Agios Pharmaceuticals, Inc.Agios Pharmaceuticals, Inc.

Insider activity · 24 months0 buys1 saleCumulative net flow

Nov 24 · 0 buys · 0 salesDec 24 · 0 buys · 0 salesJan 25 · 0 buys · 0 salesFeb 25 · 0 buys · 0 salesMar 25 · 0 buys · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 0 buys · 0 salesJun 25 · 0 buys · 0 salesJul 25 · 0 buys · 1 saleAug 25 · 0 buys · 0 salesSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 0 buys · 0 salesDec 25 · 0 buys · 0 salesJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 0 salesMar 26 · 0 buys · 0 salesApr 26 · 0 buys · 0 salesMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 0 buys · 0 salesSept 26 · 0 buys · 0 salesOct 26 · 0 buys · 0 sales

Total declarations

Company

▲ Purchases (0 ops.)

—

▼ Sales (1 ops.)

€48k

Latest filing published 23 Jun 2026 for Agios Pharmaceuticals, INC.. Read the official filing

Filing timeline

BuySale

David Scadden

Insider track record

Disclosed buys

Disclosed sells

Not enough buy signals with a settled T+90 horizon to measure a track record yet.

Signal history

David Scadden: trading record in brief

David Scadden (board member) discloses dealings in Agios Pharmaceuticals, Inc. to SEC (Form 4). Between 28 May 2021 and 18 June 2026, the trades on record add up to 13 filings.

No open-market purchase appears, only 1 sale worth €48k. Other entries cover 12 option exercises.

The newest entry dates from 23 June 2026: an option exercise, in Agios Pharmaceuticals, Inc. The median gap between a trade and its publication by SEC (Form 4) is 3 days. The legal deadline for a Form 4 is two business days after the transaction. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.